USP Launches Trust Accelerated Program to Help COVID-19 Treatment, Vaccine Development

To accelerate the development of safe and effective COVID-19 vaccines, medicines and other treatments, the U.S. Pharmacopeia (USP) has launched a new program to support scientists, developers and manufacturers worldwide.

Trust Accelerated offers expanded access to free USP technical expertise and resources to support a path for regulatory predictability, saving developers time and resources. Designed to expedite efforts to bring life-saving vaccines and treatments to market while ensuring quality development, the program builds the confidence and trust of healthcare practitioners and patients necessary for wide-scale adoption.

“Overcoming the COVID-19 pandemic will require rapid development of safe and effective treatments—in particular a vaccine—and ensuring their availability at sufficient scale,” said Jaap Venema, USP executive vice president and chief science officer. “Whether working on a new medicine or scaling up production of an approved therapeutic, recognizing and addressing quality challenges early in the complex research and development process are critical to accelerating any drug development program.”

Available resources include:

• New users can access the United States Pharmacopeia–National Formulary (USP–NF) Online free for six months.

• On-demand USP training and education is available at a 75% discount. Courses include analytical method validation and pharmaceutical quality practices. To access, register for a free account.

Additionally, USP scientific staff can help troubleshoot many quality-related challenges commonly encountered during development and scale-up, ultimately supporting manufacturers as they advance their strategies to manage regulatory and compendial expectations.